Cell video thumbnail for CD34+ cell therapy publications


Merger Related Publications

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

CD34+ Cell Technology

Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction

Transplantation of CD34+ cells for myocardial ischemia

Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair—A Systematic Review

Testing for Coronary Microvascular Dysfunction

Show More

Related Cardiovascular Publications

Contemporary Management of Refractory Angina

Definition and epidemiology of coronary microvascular disease

Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Gender in CV Medicine

Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis

Pathophysiology of Coronary Microvascular Dysfunction

Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases

Patient Perspective: Maria George founder of INOCA International

Treatment of coronary microvascular dysfunction

Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies.

Stem Cells in the Treatment of Disease

The Impact of Cell Therapy on Cardiovascular Outcomes in Patients With Refractory Angina

Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review

Treatment of angina and microvascular coronary dysfunction

Show More


Guest Commentary: Building a Problem or a Solution?

Agency Meetings with the US Food and Drug Administration